A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study

https://doi.org/10.1016/S0002-9343(99)80399-4Get rights and content

Purpose

Studies of the efficacy of hydroxychloroquine in rheumatoid arthritis have had methodological flaws and have failed to produce definitive results. The benefits and toxicity of hydroxychloroquine sulfate in 120 patients with rheumatoid arthritis of less than 2 years duration are assessed.

Patients and methods

A 36-week randomized double-blind, placebo-controlled trial was conducted at two university centers and four community rheumatology private practices. Patients had to have had their disease for less than 2 years and to have never received a second-line drug. Patients were randomly assigned to receive hydroxychloroquine or an equivalent number of placebo tablets in a dose of up to 7 mg/kg per day (maximum 400 mg/day). The initial dose was half the maximum dose and, if after 2 weeks of treatment there had been no side effects, the full dose was prescribed. There were four a priori primary outcomes: (1) a joint index composed of the tender joint count, the swollen joint count, the grip strength, and the duration of morning stiffness; (2) a pain index composed of the pain dimension of the Arthritis Impact Measurement Scales (AIMS) and the visual analog pain scale of the Health Assessment Questionnaire (HAQ); (3) a physical function index composed of the HAQ, the physical disability dimension of the AIMS, and the McMaster-Toronto Arthritis Patient Performance Disability Questionnaire; (4) the psychological function subscale of the AIMS. Secondary outcomes included adverse events, patient and physician global assessments, hematocrit, erythrocyte sedimentation rate (ESR) and corticosteroid usage. An intent-to-treat analysis assessed improvement at 36 weeks by Student's t-test and average improvement over the course of the study by analysis of variance for repeated measures.

Results

Of 148 eligible patients, 120 were randomized. The characteristics of those randomized to hydroxychloroquine compared to placebo were similar at the study onset. At 36 weeks and over the course of the study there was statistically significant improvement in the joint index (P = 0.004, P = 0.034, respectively), the pain index (P = 0.007, P = 0.001, respectively), and the physical function index (P = 0.020, P = 0.011, respectively) in the group receiving hydroxychloroquine compared to the placebo group. There was no improvement in psychological function for hydroxychloroquine compared to placebo (P = 0.837 at 36 weeks, P = 0.89 over the course of the study). Among the secondary outcomes there was significant improvement only in the patient's (P = 0.01) and the outcome assessor's (P = 0.03) assessment of change and a trend towards a fewer number of intra-articular corticosteroid injections (P = 0.05) in the hydroxychloroquine-treated group. There were no important differences in the side effects between hydroxychloroquine or placebo.

Conclusion

Over 36 weeks, hydroxychloroquine had a significant benefit on synovitis, pain, and physical disability of recent-onset rheumatoid arthritis, but did not benefit psychological function.

References (37)

  • MeenanRF et al.

    The clinical and health status of patients with recent onset rheumatoid arthritis

    Arthritis Rheum

    (1991)
  • DavisMJ et al.

    Should disease modifying agents be used in mild rheumatoid arthritis

    Br J Rheumatol

    (1991)
  • HusainZ et al.

    Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole

    J Rheumatol

    (1980)
  • WolfeF et al.

    Termination of slow-acting anti-rheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts

    J Rheumatol

    (1990)
  • SinghG et al.

    Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis

    J Rheumatal

    (1991)
  • ArnettFC et al.

    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

    Arthritis Rheum

    (1988)
  • SteinbrockerO et al.

    Therapeutic criteria in rheumatoid arthritis

    JAMA

    (1949)
  • KlinkhoffAV et al.

    An experiment in reducing interobserver variability of the examination for joint tenderness

    J Rheumatol

    (1988)
  • Cited by (160)

    • Hyperlipidemia and rheumatoid arthritis

      2022, Cholesterol: From Chemistry and Biophysics to the Clinic
    • The neurology of lupus

      2021, Journal of the Neurological Sciences
      Citation Excerpt :

      Two large, prospective, observational cohort studies of SLE [66,69] have reported a lower risk of seizures in patients with SLE taking antimalarial drugs, even after adjusting for potential confounding variables. The precise mechanism responsible for this beneficial effect is not clear but it may result from a combination of the known anti-inflammatory [70,71] and antithrombotic [72] properties of antimalarial drugs. These rare manifestations of SLE occur in 0.7–3% of patients.

    • Nervous system

      2021, Lahita’s Systemic Lupus Erythematosus
    • Hydroxychloroquine safety: A meta-analysis of randomized controlled trials

      2020, Travel Medicine and Infectious Disease
      Citation Excerpt :

      Eight RCTs were double-blind [11–18], and one was single-blind [10]. Only three RCTs were funded by drug companies [11,12,18]. Studies were conducted on four different continents and included patients with a variety of indications.

    View all citing articles on Scopus
    *

    The HERA Study Group includes; Principal Investigators and Coordinating Center: John M. Esdaile, MD, MPH, Samy Suissa, PhD, Jeffrey B. Shiroky, MD, Donna Lamping, PhD, Montreal; Project Director: Eva Tsakonas, MSc, Montreal; Consultant Ophthalmologist: Duncan Anderson, MD, Montreal; Consultant Pharmacokineticist: Fakheredin Jamali, PhD, Edmonton; External Monitoring Committee: Matthew H. Liang, MD, MPH, (Chairman), Boston; Simon Carette, MD, Quebec City; Center Investigators: Alfred Cividino, MD, Hamilton; Avril Fitzgerald, MD, Edmonton; Abdelmajid M'Seffar, MD, Montreal; Mary-Ann Fitzcharles, MD, Montreal; John M. Esdaile, MD, MPH, Montreal; Claire Bombardier, MD, Toronto; Carter Thorne, MD, Newmarket; Center Coordinators: Marylin Bell, Lisa Ros, RN, Hamilton; Joyce Lakeman, RN, Edmonton; Dina Perron, Lidia Sunac-Ferguson, RN, Lise Robidoux, RN, Montreal; Vicki Lapp, RN, Toronto and Newmarket; Center Outcome Evaluators: Mary J. Bell, MD, Hamilton; Stephen Aaron, MD, Edmonton; Michel Zummer, MD, Montreal; Michael Starr, MD, Montreal; Kathy Jarka, PhT, Montreal; Deborah Weber, RN, and Da Wen Hu, MD, Toronto and Newmarket; Center Ophthalmologists: Mark Gans, MD, Montreal; Lawrence E. Kobetz, MD, Hamilton; David Climenhaga, MD, Edmonton; Michael Easterbrook, MD, Toronto; Leslie Landecker, MD, Newmarket.

    View full text